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ABSTRACT 
Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting 
in an increased risk of fragility fractures, most of which are located in the lumbar spine. 
Bioresorbable calcium phosphate cement (CPC), mechanically stabilized by the addition of    
poly(l-lactide-co-glycolide) acid (PLGA) fibers, may be suitable for the vertebroplasty/kyphoplasty 
of osteoporotic vertebral fractures. However, additional targeted delivery of osteoinductive bone 
morphogenetic proteins (BMPs) in the CPC may be required to counteract the augmented local 
bone catabolism and support complete bone regeneration. 
The present work thus aimed at: 1) analyzing the release kinetics of three BMPs (GDF5, BB-1 and 
BMP-2) from an injectable brushite-forming PLGA fiber-reinforced CPC and their bioactivity in 
vitro; 2) generating and characterizating a minimally invasive large animal sheep model for lumbar 
ventrolateral vertebroplasty; and 3) testing the PLGA-fiber reinforced CPC loaded with low-dose 
BMP-2 in the newly established model. 
The quantification of the release by ELISA within 30/31 days showed a maximum of 34% and 17% 
of the applied dosages (2, 10, 200, and 1000 µg/ml) respectively, for GDF5 and BB-1 (BMP-2: 
25.7% release of 400 µg/ml within 14 days).The addition of 5% and 10% PLGA fibers augmented 
the BMP release within 14 days. Notably, in several cell lines the BMPs released within 3 days 
demonstrated bioactivity, in selected cases augmented by the addition of 10% fibers. In order to 
develop a large animal model suitable for preclinical studies, lumbar defects were created by a 
ventrolateral percutaneous approach in aged, osteopenic, female sheep (L1: untouched; L2: empty 
defect; and L3: CPC). The minimally invasive model resulted in short operation time and 
postoperative recovery, very limited local trauma, and high experimental reproducibility.  
The model was then used for the vertebral injection of CPC containing different dosages of BMP-2 
(1, 5, 100, and 500 µg). Three and 9 months after operation, BMP-2 improved all parameters of 
bone formation, bone resorption, and bone structure, as well as the compressive strength. The 
BMP-2 effects on bone formation were dose-dependent, with 5 to 100 µg as the optimal dosage. 
Overall the results confirmed the suitability of the drug-loaded CPC as a carrier for a one-time 
delivery of osteogenic proteins such as BMP-2 in minimally invasive surgery. Thus, the new CPC 
may represent an alternative to the bioinert, supraphysiologically stiff polymethylmethacrylate 
cement currently used to treat osteoporotic vertebral fractures by vertebroplasty/kyphoplasty.  
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ZUSAMMENFASSUNG 
Osteoporose ist durch eine verminderte Knochenmasse und gestörte Knochenarchitektur 
charakterisiert. Dies führt zu einem erhöhten Risiko für Knochenbrüche, die am häufigsten in der 
Lendenwirbelsäule auftreten. Ein durch Poly(lactid-co-glycolid) (PLGA) Fasern mechanisch 
stabilisierter, bioresorbierbarer Calcium-Phosphat Zement (CPC) könnte für die Behandlung von 
osteoporotischen Wirbelkörperfrakturen mittels Vertebroplastie/Kyphoplastie geeignet sein. 
Trotzdem ist möglicherweise eine zusätzliche, gezielte Bereitstellung von osteoinduktiven 
Wachstumsfaktoren (bone morphogenetic proteins; BMPs) in dem CPC notwendig, um dem 
erhöhten lokalen Knochenabbau entgegenzuwirken und die komplette Knochenregeneration zu 
unterstützen. Die Ziele der vorliegenden Arbeit waren daher: 1) die Analyse der 
Freisetzungskinetik von drei BMPs (GDF5, BB-1 und BMP-2) aus einem injizierbaren, Brushit-
bildenden, PLGA-Faser verstärkten CPC und deren Bioaktivität in vitro; 2) die Etablierung und 
Charakterisierung eines minimal-invasiven Großtiermodells im Schaf für die lumbale 
ventrolaterale Vertebroplastie; und 3) die Testung eines PLGA-Faser verstärkten, mit niedrig 
dosiertem BMP-2 beladenen CPC in dem neu etablierten Modell.  
Die Quantifizierung der Freisetzung mittels ELISA zeigte, dass innerhalb von 30/31 Tagen max. 
34% der eingesetzten Konzentrationen (2, 10, 200 und 1000 µg/ml) von GDF5 bzw. 17% von BB-
1 freigesetzt wurden (BMP-2: 25.7% Freisetzung von 400 µg/ml innerhalb von 14 Tagen). Der 
Zusatz von 5 und 10% PLGA Fasern verstärkte die BMP Freisetzung innerhalb von 14 Tagen. 
Bemerkenswerterweise zeigten die innerhalb von 3 Tagen freigesetzten BMPs in verschiedenen 
Zell-Linien Bioaktivität, die in ausgewählten Fällen durch den Zusatz von 10% Fasern verstärkt 
wurde.                                                                                                                                               
Zur Entwicklung eines für präklinische Studien geeigneten Großtiermodells wurden über einen 
ventrolateralen perkutanen Zugang lumbale Defekte in alten osteopenischen weiblichen Schafen 
erzeugt (L1: unbehandelt; L2: Leerdefekt; und L3: CPC). Dieses minimal-invasive Modell 
resultierte in einer kurzen Operationszeit und postoperativen Erholungsphase, sehr begrenztem 
lokalen Trauma und hoher experimenteller Reproduzierbarkeit.  
Das Modell wurde dann für die vertebrale Injektion von CPC mit verschiedenen Dosierungen von 
BMP-2 benutzt (1, 5, 100, und 500 µg). Drei und 9 Monate nach der Operation verbesserte BMP-2 
alle Parameter der Knochenbildung, Knochenresorption und Knochenstruktur sowie die 
Druckfestigkeit. Die BMP-2 Effekte auf die Knochenbildung waren dosisabhängig, mit 5 bis 100 
µg als der optimalen Dosierung. 
Zusammenfassend bestätigten die Resultate die Eignung des Wirkstoff-beladenen CPC als Träger 
für die einmalige Bereitstellung von osteogenen Proteinen wie z.B. BMP-2 in minimal-invasiver 
Chirurgie. Daher könnte der neue CPC eine Alternative für den bioinerten, supraphysiologisch 
steifen Polymethylmethacrylat-Zement darstellen, der derzeit für die Behandlung von 
osteoporotischen Wirbelkörperfrakturen mittels Vertebroplastie/Kyphoplastie eingesetzt wird. 
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1. INTRODUCTION 
1.1 Osteoporosis 
Osteoporosis, literally “porous bone”, is a systemic skeletal disease regarded as a major 
socioeconomic health problem worldwide, characterized by the loss of bone mass leading to high 
individual disease load and severely impaired quality of life (Reginster and Burlet 2006, Hernlund, 
Svedbom et al. 2013). The considerably reduced bone mass and disturbed microarchitecture results 
in a loss of mechanical strength and increased fracture risk (Hernlund, Svedbom et al. 2013). There 
are different ways in which osteoporosis can develop and lead to a more fragile skeleton 
(Unnanuntana, Rebolledo et al. 2011). Studies of bone turnover have shown that the major cause of 
decreased bone mass in human osteoporosis is not the decrease in bone formation, but rather an 
increase in bone resorption (Hernlund, Svedbom et al. 2013). During childhood and adolescence, 
bone deposition exceeds bone resorption, so that the skeleton grows in size and bone mineral 
density (BMD). Up to 90 percent of the peak bone mass is acquired by age 18 in girls and by age 
20 in boys, which makes youth the best time to “invest” in the individual’s bone health. The 
amount of bone tissue in the skeleton, known as bone mass,  keeps increasing until around age 30 
(Sykaras and Opperman 2003). At that point, bones have reached their maximum strength and 
density, known as peak bone mass. Factors such as hormones (Riggs, Jowsey et al. 1969), nutrition 
(Cashman 2007), and physical exercise (Englund, Littbrand et al. 2009) can dramatically affect the 
peak bone mass. Women tend to experience only minimal loss of total bone mass between age 30 
and menopause. But in the first few years after menopause, most women go through rapid bone 
loss, which then slows, but continues throughout the postmenopausal years. This loss of bone mass 
leads to a condition called osteopenia, which becomes osteoporosis when mechanical demands 
exceed the stability of the skeletal structure (Urist 1965).  
                                                    
                            
Figure 1.1: Peak bone mass and bone loss according to age for men and women. [Kruger MJ, Nell 
TA. Bone mineral density in people living with HIV: a narrative review of the literature. AIDS Res 
Ther 2017:14(1)35] 
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Osteoporosis has been operationally defined on the basis of BMD assessment. According to the 
World Health Organization (WHO) criteria, it is defined as a BMD that lies 2.5 standard deviations 
or more (T-score of < -2.5 SD) below the average peak bone mass for the young healthy population 
[age of approximately 30; (Namkung-Matthai, Appleyard et al. 2001)]. This criterion has been 
widely accepted, and provides both a diagnostic and an intervention threshold. Based on BMD 
values, ranging from grade 0 (normal bone density) to grade 3 (severe osteoporosis), the WHO 
introduced a classification of osteoporosis, in which different forms can be recognized (Table 1.1). 
Due to its prevalence worldwide, osteoporosis is considered a serious public health concern. 
Currently it is estimated that over 200 million people worldwide suffer from this disease 
(Hernlund, Svedbom et al. 2013). The prevalence of osteoporosis among women in the largest 
countries in the European Union (Germany, France, Italy, Spain, and UK; EU5) using the WHO 
criteria is shown in Table 1.2. 
The treatment of osteoporosis consists of a combination of antiresorptive and anabolic agents 
(estrogen receptor modulators and bisphosphonates); however, it is important to recognize that 
non-pharmacologic approaches are also needed to limit the fracture risk (Rizzoli, Branco et al. 
2014). They include: maintaining adequate intake of calcium, vitamin D, and protein; using proper 
techniques when lifting; performing adequate weight-bearing physical activity and exercise to 
maintain or improve balance and posture; making appropriate lifestyle changes, such as smoking 
cessation and moderating alcohol intake. 
 
 
                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1: World Health Organization (WHO) criteria for diagnosing osteoporosis using bone 
density measurements. [Kanis JA, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994; 
9:1137–1141] 
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Age group (years) France UK Germany Italy Spain EU5 
50-54 135 127 192 128 95 695 
55-59 200 175 265 180 126 974 
60-64 286 276 328 276 175 1,385 
65-69 271 308 489 335 215 1,672 
70-74 364 65 718 464 270 2,236 
75-79 484 411 672 546 368 2,543 
80-84 526 417 686 558 357 2,612 
50-84 2,266 2,079 3,350 2,487 1,606 12,117 
 
Table 1.2: Number (in thousands) of women with osteoporosis according to age in the 
European Union Five (EU5) countries using female-derived reference ranges at the femoral 
neck. [Ström O, et al. Osteoporosis: burden, health care provision and opportunities in the EU: 
a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and 
the European Federation of Pharmaceutical Industry Associations (EFPIA), 2011]                  
 
1.2 Osteoporotic vertebral compression fractures      
Osteoporosis increases the number of atraumatic fractures and contributes to the severity of 
traumatic fractures. The clinical fracture threshold is reached at a loss of cancellous bone mass 
of > 40%, leading to fractures mostly localized in the lumbar spine (Bush 1991). The incidence 
of clinically diagnosed vertebral fractures rises steeply with age and the female to male 
incidence ratio after age adjustment is around 2:1 (Cooper and Melton 1992). A 50-year-old 
white woman has a 32% risk of suffering from a vertebral fracture during her remaining lifetime 
(Cummings, Black et al. 1989). Untreated vertebral compression fractures can cause debilitating 
back pain, spinal deformity, disability, reduction of respiratory function, and increased risk of 
death (Leidig, Minne et al. 1990). Although the impact of the vertebral compression fractures on 
health remains to be accurately quantified, a considerable number of patients suffer from long-
term pain and disability. Moreover, osteoporosis can impair social relations, which in turns 
contributes to the development of severe depression (Gold 1996). The adverse effects of 
osteoporotic fractures are likely to increase in the future with the growing number of elderly 
people (Melton 1997). 
 
1.2.1 Fracture healing 
Bone heals by a regenerative process to restore the metabolic and mechanical functions of the 
injured tissue (Fig. 1.2). Immediately following a trauma, localized tissue hypoxia occurs 
(Einhorn and Gerstenfeld 2015), and a hematoma is generated which consists of cells from both 
peripheral and intramedullary blood, as well as bone marrow cells. The injury initiates an 
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inflammatory response, which is necessary for the healing to progress (Fig. 1.2A). The response 
causes the hematoma to coagulate in between and around the fracture ends, as well as within the 
medulla, forming a template for callus formation (Gerstenfeld, Cullinane et al. 2003).  
 
 
Figure 1.2: A spatiotemporal cascade of multiple endogenous factors controls normal bone 
regeneration during fracture repair in four stages. PDGF = platelet derived growth factor;        
VEGF = vascular endothelial growth factor; FGF = fibroblast growth factor; TNF = tumor necrosis 
factor; SDF = stromal cell-derived factor; IGF = insulin-like growth factor; BMP = bone 
morphogenetic protein; OPG = osteoprotegerin; IL = interleukin; TGF = transforming growth 
factor; Ang = angiopoietin; M-CSF = macrophage colony stimulating factor; RANK = receptor 
activator of nuclear factor kB; RANKL = RANK-ligand. [Newman MR et al. Curr Opin Biotechnol 
2016; 40:125-132] 
 
Although prolonged or chronic expression of inflammatory cytokines has negative effects on bone, 
joints, and implanted material, a brief and highly regulated secretion of proinflammatory molecules 
following acute injury is critical for tissue regeneration (Gerstenfeld, Cullinane et al. 2003). The 
acute inflammatory response peaks within the first 24 hours and is largely completed after 7 days, 
although proinflammatory molecules also play an important role in later phases of the regeneration 
process (Cho, Kim et al. 2007). The initial proinflammatory response involves secretion of tumor 
necrosis factor-α (TNF-α), interleukin-1 (IL-1), IL-6, IL-11, and IL-18 (Gerstenfeld, Alkhiary et al. 
2006), which recruit inflammatory cells and promote angiogenesis (Fig. 1.2A-B). Following the 
formation of the primary hematoma, a fibrin-rich granulation tissue is formed. Within this tissue, 
endochondral formation of cartilage occurs in between the fracture ends and outside of the fracture 
below the periosteum. The granulation tissue is also mechanically less stable, whereas the 
cartilaginous tissue forms a soft callus which already gives the fracture a stable structure 
A B C D 
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[(Dimitriou, Tsiridis et al. 2005); Fig 1.2B]. At the same time, an intramembranous, subperiostal 
ossification response occurs directly adjacent to the distal and proximal ends of the fracture, 
generating a hard callus (Fig. 1.2C). It is the final bridging of the hard callus that ultimately 
provides the fracture with a semi-rigid structure, which allows weight bearing [(Gerstenfeld, 
Alkhiary et al. 2006); Fig. 1.2D]. The generation of the callus tissue is dependent on the local 
recruitment of mesenchymal marrow stem cells (mMSCs) from surrounding soft tissues, cortex, 
periosteum, and bone marrow, as well as the systemic supply of stem cells from the circulation 
following their mobilization into the peripheral blood from remote hematopoetic sites. Fracture 
callus mMSCs adjacent to the newly formed bone and the periosteum differentiate into 
chondrocytes, shaping an early fracture callus with new bone at its periphery, fibroblast-like cells 
in its center, and chondrocytes sandwiched in between these two layers. As healing progresses, 
differentiation of the fracture callus cells into chondrocytes proceeds from the periphery of the 
callus and the original periosteum towards the center and the circumferential edges of the callus. 
Chondrocytes closest to the periosteum and new bone are the first to become hypertrophic and 
form calcified cartilage. Osteoblasts derived from the pre-existing bone beneath the calcified 
cartilage, form bone on the calcified cartilage stratum until the fracture gap is bridged with new 
bone. Subsequent bone remodeling enhances the mechanical properties of the newly formed bone 
and returns it to its former shape. During this process, transforming growth factor-beta (TGF-β) 
superfamily members are pivotal. TGF-β2, -β3, and GDF5 are involved in chondrogenesis and 
endochondral ossification, whereas BMP-5 and BMP-6 have been suggested to induce osteoblast 
proliferation and intramembranous ossification at periosteal sites (Cho, Gerstenfeld et al. 2002, 
Marsell and Einhorn 2009).  
Although bone is one of the few organs in the body that can spontaneously heal and restore 
function without scarring, bone healing is unsuccessful when the bone loss produces a critical-size 
defect (i.e., a defect exceeding the healing capacity of a few millimeters in human; or even in cases 
of non critical-size defects in elderly people and people affected by diabetes, nicotin abuse, 
compromised vascularity or osteoporosis).  
 
1.2.2 Cellular and molecular basis of osteoporosis 
A limited fracture healing capacity in osteoporosis is known from animal studies (Walsh, Sherman 
et al. 1997, Namkung-Matthai, Appleyard et al. 2001), and is associated with a dramatically 
increased failure rate of implant fixation (Barrios, Brostrom et al. 1993). The age-related bone loss 
resulting in osteoporotic vertebral compression fractures is based on a dysbalance between the 
underproduction of osteoblasts and the subsequently diminished bone formation on one hand, and 
the overproduction and overactivation of osteoclasts with augmented bone resorption on the other 
hand (Egermann, Schneider et al. 2005). In this context, estrogen deficiency seems to play an 
important role in the pathogenesis of osteoporosis and osteoporotic fractures (Augat, Simon et al. 
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2005). Osteoblasts and mMSC osteoblast precursors (Komm, Terpening et al. 1988), osteocytes 
(LeGeros 1982), and osteoclasts (del Real, Wolke et al. 2002) all express functional estrogen 
receptors (ERs). This may be the basis for the finding that mMSCs from post-menopausal women 
have a lower growth rate and a deficient ability to differentiate along the osteogenic lineage in 
comparison to mMSCs from pre-menopausal women (Rodriguez, Garat et al. 1999). In addition, 
aging decreases the expression of osteoblast- specific transcription factors such as Runx2 and Dlx5 
in mMSCs, but increases the expression of the adipocyte-specific transcription factor PPARγ2. 
Both changes decrease the number of mMSC-derived osteoblasts, but increase the number of 
mMSC-derived adipocytes (Moerman, Teng et al. 2004) and thus decrease the ratio between these 
two cell populations. This creates unfavorable conditions for bone stem cell participation in 
fracture repair and commonly leads to a failure of osteoporotic fractures to heal (Egermann, 
Schneider et al. 2005). It is now clear that ligand binding to ERs induces a conformational change 
that promotes receptor dimerization and binding to specific DNA promoter sequences called 
estrogen response elements [EREs; (Smith and O'Malley 2004)]. The ligand-bound receptor then 
forms a complex with coactivator proteins, which activates the general transcriptional machinery 
and increases the expression of target genes through chromatin remodeling. ERs can also recruit 
corepressors, which negatively regulate ER-dependent gene expression. In addition to this classical 
modality of gene activation, alternative mechanisms account for estrogen’s ability to both stimulate 
and repress the expression of genes encoding critical osteoclastogenic factors such as IL-6, TNF-α, 
and M-CSF (Stein and Yang 1995). Although many estrogenic effects are mediated by nuclear 
ERs, some responses originate in the plasma membrane. In fact, estrogen induces rapid non-
genomic effects (within seconds or minutes) in various cell types, including bone cells, which are 
mediated by signaling through a membrane receptor. Estrogen’s ability to inhibit osteoblast 
apoptosis, but to induce osteoclast apoptosis, is linked to its ability to increase ERK1 and ERK2 
phosphorylation and repress JNK activity (Kousteni, Bellido et al. 2001, Kousteni, Han et al. 
2003). 
The result of estrogen deficiency is thus a dramatic elevation in the number of basic multicellular 
units (BMUs), defined anatomical spaces in which bone remodelling occurs, through increased 
activation frequency of osteoclasts [number of new remodeling units activated in each unit of time; 
(Weitzmann 2006)]. The enhanced activation frequency of osteoclasts expands the remodeling 
space, increases cortical porosity, and enlarges the resorption area on trabecular surfaces. This 
phenomenon is primarily caused by increased osteoclast formation, but also by increased osteoclast 
recruitment to bone surfaces (Weitzmann 2006). Estrogen deficiency also augments the erosion 
depth by prolonging the resorption phase of the remodeling cycle through increased osteoclast 
lifespan due to reduced apoptosis (Hughes, Dai et al. 1996).  
Although estrogen has direct effects on bone cells, animal studies have identified additional 
unexpected regulatory effects of estrogen centered at the level of the adaptive immune response 
  
14 
               
(Cenci, Toraldo et al. 2003), with the potential of indirectly influencing bone formation and 
resorption.  
However, subtle differences in the genetic code and environmental factors may explain why one 
person’s osteoblasts or osteoclasts are more active or responsive to their environment and thus, 
why estrogen deficiency in postmenopausal women does not necessarily lead to osteoporosis. 
In addition, in older people angiogenesis is impaired, due to age-related changes in the hemostatic 
cascade, growth factor expression, and endothelial cell formation (Reed and Edelberg 2004). These 
changes result in delayed and impaired neovascularization and are therefore also likely to have an 
impact on wound and fracture healing in older people.  
However, estrogen deficiency after menopause is not the only reason for osteoporosis since 
osteoporosis also affects men. By age 65 or 70, men and women are losing bone mass at the same 
rate as the absorption of calcium decreases (Nordin 1997). Such a decrease with age could be due 
to: 1) a decline in serum calcitriol, possibily due to a declining renal function; 2) a reduced 
gastrointestinal response to calcitriol; 3) a decline in serum 25-Hydroxyvitamin D3 (25OHD3) due 
to low exposure to sunlight and/or a lower capacity of the skin to synthetize vitamin D; and 4) in 
the case of men, a decrease in testosteron levels.  
The receptor activator nuclear factor-κB ligand (RANKL) as a regulator of osteoclast activity, is 
also involved in the pathogenesis of osteoporosis and thus represents a new therapeutic target 
(McClung 2007). By binding to its receptor RANK on osteoclastic precursors, RANKL controls 
the differentiation, proliferation, and survival of osteoclasts. Mice that are deficient in 
osteoprotegerin (OPG), a natural inhibitor of RANKL, exhibit osteoporosis, whereas over-
expression of OPG in mice results in reduced numbers of osteoclasts and high bone mass      
(Simonet, Lacey et al. 1997, Bucay, Sarosi et al. 1998). Perturbations in the ratio of OPG to 
RANKL have been demonstrated to occur with estrogen deficiency, hyperparathyroidism, and 
other disorders that stimulate bone resorption (Hofbauer, Gori et al. 1999, Hofbauer, Khosla et al. 
1999). RANKL is also expressed by lymphocytes and synovial fibroblasts and may mediate bone 
loss associated with inflammatory conditions (Kong, Feige et al. 1999, Takayanagi, Iizuka et al. 
2000). 
  
1.2.3 Treatment of osteoporotic vertebral fractures: vertebroplasty/kyphoplasty 
Therapeutic options for acute vertebral body fractures include established surgical procedures such 
as spondylodesis. However, innovative, minimally invasive methods  such as  vertebroplasty and 
balloon-kyphoplasty are increasingly used (Phillips, Pfeifer et al. 2003). The latter are 
advantageous because they allow: 1) reduction of the hospitalization time compared to the 
traditional “open surgery” in which the vertebrae are exposed by an incision through the skin and 
muscles; 2) clear improvement of lumbar biomechanics in the large majority (90%) of the patients; 
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and 3) rapid and substantial reduction of pain (Lavelle, Khaleel et al. 2008). Significant pain relief 
usually occurs within 24 h after treatment (Cotten, Boutry et al. 1998). 
The standard treatment for vertebral compression fractures consists of conservative management, 
including bed rest, bracing, and analgesics to relieve pain and regain functions of daily living 
(Boonen, Wahl et al. 2011). However, these practices are often insufficient in improving pain and 
mobility (Lyritis, Mayasis et al. 1989, Hallberg, Rosenqvist et al. 2004). In addition, long-term use 
of narcotic analgesics and anti-inflammatory drugs is poorly tolerated by elderly patients. Narcotics 
may result in sedation and impaired balance increasing the risk of falling and additional fractures. 
Prolonged bed rest may cause bone loss that exacerbates the underlying disease state (Krolner and 
Toft 1983), and can lead to rapid deconditioning, pulmonary compromise and increased mortality 
(Lau, Ong et al. 2008). Operative interventions such as open surgical fusions and the use of metal 
implants to treat unstable vertebral compression fractures have thus gained popularity (Deyo 2010); 
however, such interventions frequently cause failures and non-unions due to the low bone quality 
in osteoporotic patients, muscle injuries, and prolonged back pain. Pain relief is the principal 
objective when treating vertebral compression fractures in the elderly population (Boonen, Wahl et 
al. 2011), and the pain intensity potentially influences a patient’s acceptance of surgical 
complication risks and thus the decision to consent to lumbar fusion (Bono, Harris et al. 2013). For 
such reasons, minimally-invasive vertebroplasty and kyphoplasty can recognizably increase the 
quality of life in patients with an osteoporotic vertebral fracture by improving lumbar biomechanics 
and stability and thus relieving pain. The technique of vertebroplasty, originally developed and 
published in 1987 by the French radiologist Galibert and the French neurologist Deramond 
(Galibert P 1987), consists of the direct percutaneous injection of a biomaterial, usually a methyl 
methacrylate cement, under pressure into a lesioned vertebral body. Percutaneous balloon 
kyphoplasty, approved by the US food and drug administration (FDA) since 1998 (Belkoff, Mathis 
et al. 2001), is a modification of this technique. The principle of kyphoplasty is to restore vertebral 
body anatomy by inflating balloons and then reinforce the anterior column of the vertebra with 
cement. The principal indications for these two procedures were initially osteolytic metastasis and 
myeloma, painful or aggressive hemangioma, and osteoporotic vertebral collapse (Cotten, Boutry 
et al. 1998). Nowadays, the main target population are patients with painful, therapy-resistant 
osteoporotic vertebral fractures not responding to analgesics, rest, bracing, or other conservative 
therapies for a period of 6 months (Voormolen, Mali et al. 2007). However, vertebroplasty is 
contraindicated in coagulation disorders due to the large diameter of the injection needle. Extensive 
vertebral destruction and significant vertebral collapse (i.e., vertebra reduced to less than one-third 
of its original height) may result in a technically challenging surgical procedure. The complication 
rate associated with both procedures is relatively low [7%; (Yaltirik, Ashour et al. 2016)], but 
serious complications can occur. These risks include spinal cord compression, nerve root 
compression, venous embolism, and pulmonary embolism including cardiovascular collapse 
(Burton and Mendel 2003). Hulme et al. reviewed 69 clinical studies and reported hardly any 
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difference between vertebroplasty and kyphoplasty concerning vertebral height restoration and pain 
relief (Hulme, Krebs et al. 2006). 
Kyphoplasty may be superior to vertebroplasty in patients with large kyphotic angles, vertebral 
fissures, fractures in the posterior edge of the vertebral body or significant height loss in the 
fractured vertebrae (Yaltirik, Ashour et al. 2016). Radiography and computed tomography (CT) 
must be performed in the days preceding vertebroplasty to assess: 1) the extent of the vertebral 
collapse; 2) the location and extent of the lytic process; 3) the visibility and degree of involvement 
of the pedicles; 4) the presence of cortical destruction or fracture, especially of the posterior wall; 
and 5) the presence of epidural or foraminal stenosis. The decision to perform such procedures 
should be made by a multidisciplinary team, because the choice among open spine surgery, 
vertebroplasty, radiation therapy, medical treatment, or a combination thereof depends on a number 
of factors.   
1.3 Calcium phosphate cements (CPCs) as a biomaterial 
Bone cements, applied as filler materials in vertebral augmentation procedures such as 
vertebroplasty and kyphoplasty, are basically self-curing systems, generally supplied as 
separately packaged powder and liquid phases and mixed prior to use during surgery. These 
materials undergo subsequent in situ polymerization following injection into the vertebral body 
and harden to provide adequate mechanical support to the vertebral column (Deb 1999). At 
present, polymethylmethacrylate (PMMA) cement is the most widely used material for 
vertebroplasty and kyphoplasty, with extensive records of in vitro and in vivo analyses (Yimin, 
Zhiwei et al. 2013). Although the use of high-viscosity PMMA cement is thought to 
significantly reduce the rate of cement leakage, it may lead to limited penetration into trabecular 
bone and thus compromise the mechanical strength of the augmented vertebral body (Baroud, 
Crookshank et al. 2006, Hulme, Krebs et al. 2006). At the same time, PMMA cement shows 
some disadvantages such as monomer toxicity, thermal necrosis caused by high polymerization 
temperatures (Belkoff, Mathis et al. 2001), lack of bioactivity and biodegradability, and risk of 
leakage or fractures in adjacent vertebral bodies (Hulme, Krebs et al. 2006, Nouda, Tomita et al. 
2009). Moreover, PMMA cement-based therapies for vertebral compression fractures may 
permanently exclude and eliminate mMSCs from the vertebral bone marrow space due to 
cellular toxicity, thus hampering endogenous bone healing. Due to such safety concerns on 
PMMA cements, calcium phosphate cement (CPC) has been used as an alternative to PMMA or 
acrylic bone cements and other injectable, drug-releasing biomaterials. In early 1980s, 
researchers discovered self-setting calcium orthophosphate cements (Table 1.3), which contain a 
powder with one or more solid compounds of calcium phosphate salts and an aqueous liquid 
(LeGeros 1982). Mixed in an appropriate ratio, a paste is formed which sets at body temperature 
by entanglement of the crystals precipitating within the paste. Therefore, calcium phosphate 
cements can be shaped according to the defect dimensions and set in situ. After setting, the 
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calcium phosphate crystals typically form a microporous structure with pores smaller than 1 µm 
(Chow 2001, del Real, Wolke et al. 2002). CPCs show several advantages: 1) excellent 
osteoconductivity for bone ingrowth and remodeling; 2) bioactivity, which means the ability to 
bind directly to the surrounding bone without the formation of fibrous tissue (Cao and Hench 
1996); 3) a setting reaction at body temperature (Bohner 2001, Blattert, Jestaedt et al. 2009); 
and 4) biocompatibility and resorbability (depending on the calcium phosphate). Once 
implanted, CPCs can be resorbed by two different mechanisms, i.e., active resorption, which is 
regulated by living cells such as osteoclasts, and/or passive resorption via chemical dissolution 
or hydrolysis in the body fluids. However, CPCs exhibit poor tensile, shear, and mechanical 
strength, which limits their applicability to non- or moderate-load-bearing situations (Canal and 
Ginebra 2011). Because of their intrinsic porosity, the strength of CPCs is lower than that of 
calcium phosphate ceramics. All these factors may contribute to a residual instability of the 
vertebral body following cement augmentation (He, Zhai et al. 2015). In addition, for minimally 
invasive in vivo application in an osteoporotic vertebra, the CPC paste must have two features 
i.e., injectability and cohesion. Injectability means that the cement paste can be extruded 
through a long, small needle (e.g., 2 mm diameter and 10 cm length) without demixing. 
Demixing occurs when the mixing fluid is too liquid compared with the size of the cement 
powder particles, resulting in filter pressing: the liquid is extruded without the CaP particles. A 
cement paste with an appropriate cohesion sets in a fluid without disintegrating. This can be 
achieved by decreasing the powder-to-liquid ratio in the preparation process. The resulting CPC 
paste is less viscous and can be more easily injected (Khairoun, Boltong et al. 1998). Thus, for 
an injectable CPC a low powder-to-liquid ratio (< 2.4) has to be maintained, which on the other 
hand limits the mechanical strength of the resulting CPC (Maenz, Kunisch et al. 2014). 
Depending upon the pH value of the self-setting paste, calcium orthophosphates (Fig. 1.3) can 
only form two major end-products after hardening: 1) at pH > 4.2, a precipitated poorly 
crystalline hydroxyapatite (HA) or calcium-deficient hydroxyapatite (CDHA); and                    
2)  at pH < 4.2, dicalcium phosphate dihydrate (DCPD), also called brushite (Xia, Grover et al. 
2006). Thus, the existing self-setting calcium orthophosphate formulations are divided into the 
two major groups of apatite-forming and brushite-forming CPCs, on the basis of which bone 
substitution materials have been developed for orthopaedic surgery (e.g., for vertebroplasty and 
lumbar fusion). Brushite cement is injectable since it hardens under physiological conditions, 
shows a high biocompatibility after implantation, and is more rapidly bio-resorbable than apatite 
cement (Elliott 1997). In contrast, the crystals in the apatite cements can be easily detached 
from the bulk of the hardened cement, especially after partial dissolution, since the force linking 
the newly formed crystals is weak. These crystals can then be ingested by osteoclasts and other 
cells (Yuan, Li et al. 2000). 
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Ca/P- 
molar 
Ratio 
 
Compounds and their abbreviations 
 
Chemical formula 
 
Solubility 
at 25° C, 
−log(Ks) 
pH 
stability 
range in 
acqueous 
solutions 
at 25° C 
   0.5 Calciumdihydrogenphosphate 
Monohydrat (MCPM) 
Ca(H2PO4 )2  · H2O 1.14 0.0-2.0 
   0.5 Calciumdihydrogenphosphate Ca(H2PO4 )2 1.14 a 
   1.0 Calciumhydrogenphosphate- 
Dihydrate, brushite 
CaHPO4  · 2H2O 6.59 2.0-6.0 
   1.0 Calciumhydrogenphosphate, 
monetite 
CaHPO4 60.90 a 
  1.33 Octacalciumphosphate Ca8 (HPO4 )2 (PO4 )4 
1. 5H2O 
96.6 5.5-7.0 
1.5 α-Tricalciumphosphate (α-TCP) α-Ca3 (PO4 )2 25.5 b 
1.5 β-Tricalciumphosphate (β-TCP) β-Ca3 (PO4 )2 28.9 b 
1.2-2.2 Amorphous calcium phosphates CaxHy (PO4 )z · 
nH2O, n=3-4,5 
23-32 5.0-12.0 (c) 
1.5–1.67 
Calcium-deficient 
hydroxyapatite (CDHA) 
Ca10−x (HPO4 )x 
(PO4 )6−x 
(OH)2−x, 0 < x < 1 
 
85.1 
 
6.5-12.0 
1.67 Hydroxyapatite (HA) Ca10 (PO4 )6 (OH)2 116.8 9.5-12.0 
2.0 Tetracalcium phosphate Ca4 (PO4 )2O 38-44 b 
         
            a  –  Stable at temperatures above 100°C  
            b  –  These compounds cannot be precipitated from aqueous solutions 
            c  –   Always metastable 
 
Table 1.3: Existing calcium orthophosphates and their main properties. [Dorozhkin SV. Calcium 
Orthophosphates: Applications in Nature, Biology and Medicine. Pan Stanford: Singapore, 
Singapore 2012] 
 
                     
Figure 1.3: Two commercial calcium orthophosphates. [Dorothzkin S, Self-Setting Calcium  
Orthophosphate Formulations, J Funct Biomater 2009; 4:209-311]   
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1.3.1 Calcium phosphate cements for bone drug delivery 
A biomaterial with an intended use as a drug carrier must have the ability to incorporate a drug, to 
retain it at a specific target site, and to deliver it progressively to the surrounding tissues. For this 
purpose, injectable and biodegradable biomaterials with an intrinsic porosity are advantageous. 
Since the hardening of the CPC takes place at room or body temperature, drugs, biologically active 
molecules or even cells can be incorporated without thermal denaturalization or loss of activity 
during preparation or implantation (Ginebra, Canal et al. 2012). These features make CPCs 
attractive candidates for a local and controlled supply of drugs in the treatment of different skeletal 
diseases, such as bone tumors, osteoporosis or osteomyelitis. 
One possibility is to homogeneously incorporate drugs into CPCs by adding them to either the 
powder or the liquid phase of the cement (Ginebra, Traykova et al. 2006). This can be achieved by 
blending drug powder with the solid phase or by dissolving it within the liquid phase, in the latter 
case usually resulting in a more homogenous distribution. When the drug is instead incorporated 
into the powder phase of the CPC, only partial dissolution of the drug particles will take place 
depending on the solubility of the drug in the reactant liquid phase of the CPC. Different 
approaches are to either incorporate the drug by impregnation of pre-set CPC solid blocks or 
granules with a drug solution or to incorporate the drug in polymeric microspheres before blending 
them with the CPC. 
CPCs can be used as carriers for different types of drugs or active principles which are classified in 
three groups: 1) low molecular weight drugs; 2) ions; and 3) high molecular weight biomolecules. 
The first group is represented by antibiotics [gentamicin (Bohner, Lemaitre et al. 2000), 
vancomycin (Hofmann, Mohammed et al. 2009), ciprofloxacin (Hofmann, Mohammed et al. 2009), 
doxycycline (Alkhraisat, Rueda et al. 2010)], non-steroidal anti-inflammatory drugs [NSAIDs, e.g., 
ibuprofen (Girod Fullana, Ternet et al. 2010), acetylsalycylic acid (Ginebra, Rilliard et al. 2001)], 
and anti-cancer drugs [cisplatin (Tahara and Ishii 2001), paclitaxel (Lopez-Heredia, Kamphuis et 
al. 2011)]. The second group is represented by ions targeting bone remodeling processes (calcium, 
phosphate, strontium, silicate, zinc, and magnesium) and ions with antimicrobial activity (e.g., 
silver) to treat and prevent infections. The third group is represented by growth factors and other 
proteins. In the last years, recombination techniques have promoted the industrial production of 
human growth factors in large quantities and high purity. However, drug carriers have to be 
tailored for the controlled administration of these factors at adequate therapeutic levels, and thus 
their vectoring toward local tissue targets and cells. In fact, a one-time application of a supra-
physiological concentration of a therapeutic protein alone does not induce tissue formation and 
regeneration, since it diffuses very rapidly from the implantation site and has a short half-life 
(Tayalia and Mooney 2009). Resorbable CPCs with a homogeneous distribution of a growth factor 
not only on their surface, but in the whole bulk of the cement, allow for a more prolonged release 
of the growth factor during degradation of the cement (Ginebra, Traykova et al. 2006) and are thus 
defined as “depot systems” (Verron, Khairoun et al. 2010). Using primary rat bone cells, Blom et 
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al. recently studied the effect of the incorporation of human recombinant TGF-β1 (rhTGF-β1) into 
a CPC composed of α-TCP, TTCP, and DCPD on the first stages of bone formation in vitro, and 
demonstrated that the addition of rhTGF-β1 stimulated the differentiation of pre-osteoblastic cells 
(Blom, Klein-Nulend et al. 2002). The stimulating effect of TGF on bone growth was later 
confirmed in preclinical animal studies (Blom, Klein-Nulend et al. 2001). Other proteins with a 
relevant function in bone tissue, such as collagen I and osteocalcin, have already been incorporated 
in CPCs with the aim of improving their biological and mechanical properties (Knepper-Nicolai, 
Reinstorf et al. 2002). Of great interest are also osteoinductive bone morphogenetic proteins 
(BMPs) from the transforming growth factor beta (TGF-beta) superfamily of genes, which can be 
delivered from the CPC to further enhance new bone formation (Verron, Khairoun et al. 2010).  
1.4  Bone morphogenetic proteins (BMPs)  
Bone morphogenetic proteins (BMPs), a unique group of glycoproteins, were first identified in the 
1960s as mediators of the osteoinductive activity of demineralized bone for ectopic bone formation 
in adult animals (Urist 1965, Reddi and Huggins 1972). This is based on their capacity to induce 
the differentiation of multipotent mesenchymal stem cells into osteoblasts, thus leading to bone 
formation even outside bone tissue.  
Currently, about 20 different BMPs have been identified and grouped into subfamilies according to 
their amino acid homology (Table 1.4). BMPs are synthesized as large inactive precursors 
containing an N-terminal signal peptide, followed by a prodomain controlling appropriate folding, 
and a C-terminal mature polypeptide (Xiao, Xiang et al. 2007). Once secreted, BMPs mainly act as 
homodimers (Bragdon, Moseychuk et al. 2011), and bind to two types of serine/threonine kinase 
receptors, namely type I  (BMPR-I) and type II receptors [BMPR-II; (Rosenzweig, Imamura et al. 
1995)]. Once bound to a BMPR-I, the ligand/receptor complex recruits BMPR-II, which in turn 
phosphorylates the BMPR-I on its cytoplasmic domain containing a glycine/serine-rich domain 
[GS domain; (Miyazono, Kamiya et al. 2010)]. The BMP signal is then transduced to target genes 
through Smad-dependent (canonical) or Smad-independent pathways (Fig. 1.4A). BMPs are potent 
growth factors and have pivotal roles in osteogenic cell differentiation and the regulation of 
bone formation, maintenance, and repair (Scarfi 2016). The osteoinductive capacity of BMPs has 
been confirmed by both in vitro studies and clinical trials (Sierra-Garcia, Castro-Rios et al. 2016). 
Genetic engineering allows the production of large amounts of BMPs for clinical use, and clinical 
trials have shown the benefits of FDA-approved recombinant human BMP-2 and BMP-7 for the 
treatment of bone defects. Several synthetic and natural biomaterials have been tested as BMP 
carriers, ranging from hydroxyapatite and organic polymers to collagen (Carreira, Zambuzzi et al. 
2015), metals, glass, and ceramics. Implantation of these protein-loaded carrier leads to cell 
adhesion and subsequent carrier degradation, which eventually releases the drug/protein at the 
specific site. However, several problems such as insufficient protein delivery or inactivation of the 
protein have been frequently reported (Agrawal and Sinha 2017). Depending on their inorganic, 
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organic, or synthetic composite nature, different carriers have different physiochemical and 
biological properties and thus show different efficacy in delivering bone morphogenetic proteins, 
with a profound influence on the clinical outcome.    
 
Name/type of BMP Characteristics of BMP 
BMP-1 
Not part of TGF-ß family; induction of  cartilage 
formation 
BMP-2 
Osteoinductive,  
osteoblast differentiation and apoptosis 
BMP-3 (osteogenin) Most abundant BMP in bone, inhibits osteogenesis 
BMP-4 Osteoinductive, lung and eye development 
BMP-5 Chondrogenesis 
BMP-6 Osteoblast differentiation, chondrogenesis 
BMP-7  
(osteogenic protein-1) 
Osteoinductive, kidney and eye development 
BMP-8 
(osteogenic protein-2) 
Osteoninductive 
BMP-9  
(growth differentiation factor-2) 
Nervous system development, autocrine- 
paracrine role in the hepatic reticulo- 
endothelial system 
BMP-10 Cardiac development 
BMP-11  
(growth differentiation factor-8)  
Neuronal tissue formation 
BMP-12 
(growth differentiation factor-7) 
Tendon-iliac tissue formation 
BMP-13 
(growth differentiation factor-6) 
Tendon and ligament-like tissue formation 
BMP-14 
(growth differentiation factor-5) 
Enhanced bone formation and tendon healing 
BMP-15 Follicle-stimulating hormone activity 
BMP-16 Skeletal repair and regeneration 
BMP-17 Data not found 
BMP-18 Data not found 
Table 1.4: Characteristics of various BMPs. [modified from Jain AP et al. Bone morphogenetic 
proteins: The anomalous molecules. J Indian Soc Periodontol 2013; 17:583-6] 
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Figure 1.4: BMP signal transduction. (A) BMP signaling pathways. A) If BMP ligands first bind 
to the type I receptor and then recruit the type II receptor, which activates TAB1/2/3 through XIAP, 
the Smad-independent MAPK pathway is activated. B) Simultaneous binding of BMP ligands to 
type I and type II receptors leads to activation of the Smad-dependent pathway. The pathway-
restricted Smads (R-Smads, Smads1, 2, 3, 5 or 8) are recruited and translocated into nuclei with the 
assistance of Smad-4 and regulate the transcription of target genes. C) If BMP ligands first bind to 
the type II receptor and then recruit the type I receptor, the Smad-dependent pathway is activated. 
Regulation of BMP signaling can occur extracellularly during the process of ligand binding to the 
receptors or intracellularly during the signal transduction by inhibitory Smads called I-Smads. (B) 
BMPs and their specific receptors. Key downstream signaling molecules of BMP/GDF are 
indicated through the use of a dendrogram tree. [Lin Y, Jiang W. Bone morphogenetic proteins in 
tumour associated angiogenesis and implication in cancer therapies Cancer Lett 2016; 
380(2):586-97] 
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1.5 Animal models of osteoporosis   
Various animal models of osteoporosis have been utilized for the preclinical testing of 
pharmaceutical agents and the evaluation of treatment options. The ideal animal model should 
mimic the anatomy, biomechanics, cell biology, and pathological changes seen in the human 
skeleton and at the same time should be reproducible, meet appropriate ethical standards, and be 
economical and efficient. Most basic investigations of osteoporosis have been conducted in rats 
(Li, Shen et al. 1997), but this model is of limited utility because it lacks true lamellar bone and 
does not show trabecular remodelling in the same way as human bone, especially in younger 
animals (Erben 1996). In addition, long-term bone loss following ovariectomy alone in the rat is 
not as dramatic as the bone loss in postmenopausal women (Thompson, Simmons et al. 1995) and 
cortical bone studies are limited due to the absence of Haversian systems. Most importantly, the rat 
is too small to permit major orthopaedic surgery. 
Consequently, there is a need for large animal models in osteoporosis-related research to facilitate 
preclinical evaluation of pharmaceutical, surgical, and mechanical treatments. To meet this 
demand, several large animals species have been used, including dogs, cats, mini-pigs, sheep, and 
non-human primates (Newman, Turner et al. 1995). In particular the sheep may be a useful model 
for bone-related studies because: 1) the size and mechanical characteristics of the sheep skeleton 
are comparable to humans, which makes their large vertebral bodies well suitable for conventional 
surgical procedures (Wilke, Kettler et al. 1997, Turner 2002); 2) older sheep display Haversian 
bone remodelling (Turner 2002); 3) sheep display similar remodeling processes and biomechanical 
behaviour (Potes 2008); 4) sheep are genetically closer to humans than rodents and mice; 5) ewes 
ovulate spontaneously and have sex hormone profiles similar to women (O´Connell 1999);            
6) sheep are relatively inexpensive to maintain, docile and easy to handle; 7) their use generally 
raises fewer ethical concerns than the use of domestic pets or non-human primates. The main 
challenge associated with the use of sheep for osteoporosis studies, however, is that they do not 
naturally attain the same degree of bone loss during their adult life (3 –10 years) as humans 
(Aerssens, Boonen et al. 1998), which have an almost 10-fold longer life span. In addition, ewes do 
not undergo menopause; therefore, ovariectomy combined with immobilization, low calcium diet, 
and weekly steroid injections (e.g., glucocorticoids) are successfully used to induce osteopenia 
and/or osteoporosis in these animals (Schorlemmer, Gohl et al. 2003). However, compared to 
existing sheep osteoporosis models with numerous design, logistic or ethical disadvantages, 
physiologically aged sheep (age 8 – 10 years) may be a suitable model of non-menopausal, senile 
osteopenia with moderately thinned bone structure, considerably diminished bone formation, and 
substantially augmented bone erosion (own unpublished work). 
In the past years, sheep have been used as a model for “open surgery” techniques, but reproducible 
and safe models of minimally invasive, percutanoeus vertebroplasty in sheep have only been 
recently developed (Bungartz, Maenz et al. 2016, Oliveira, Potes et al. 2016). However, several 
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anatomic differences from human vertebrae have to be taken into consideration. Because of the 
orientation angle of the lumbar facet joints and pedicles, as well as the relatively short and 
sagittally oriented pedicles, a conventional transpedicular approach is associated with the risk of 
pedicle fracture and vertebral foramina disruption. In addition, the access angle is limited, resulting 
in smaller and isolated defects (Oliveira, Potes et al. 2016), and a higher risk of cement leakage into 
the vertebral foramen (Benneker and Hoppe 2013). To overcome these limitations, a parapedicular 
approach (Fig. 1.5) and proper sizing of the instruments are recommended (Carreira, Zambuzzi et 
al. 2015).  
 
 
                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Surgical approaches to the vertebral body. A) Axial view of the needle trajectory for 
the transpedicular approach. B) Axial view of the ideal needle trajectory for the parapedicular 
approach. C) Posterior view of the spine showing both the transpedicular (superior) and 
parapedicular (inferior) points of entry. [https://clinicalgate.com/osteoporotic-fractures] 
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2. AIM OF THE WORK 
Calcium phosphate cements (CPCs), first described in the 1980s, have been successfully used in 
the clinical field as bone filling material and represent a promising alternative to PMMA for the 
surgical treatment of osteoporotic vertebral compression fractures since they are biodegradable, 
have a Young modulus comparable with that of cancellous bone, and are regarded as 
osteoconductive by providing a scaffold for the formation of new bone. Own studies have recently 
demonstrated that the incorporation of PLGA fibers in a brushite-forming CPC on one hand results 
in an increase of diametral tensile strength, biaxial flexural strength, flexural strength, and work of 
fracture (Fig. A.2), and on the other hand enhances bone formation upon in vivo application. To 
further stimulate bone formation, the CPC can be used as a carrier system for osteoinductive 
growth factors such as bone morphogenetic proteins (BMPs). The main aim of the present work is 
the development of a BMP-containing CPC which shows high biocompatibility and 
osteoinductivity and is suitable for the stabilization of osteoporotic compression fractures. 
 
The thesis is structured in three parts based on published or submitted papers: 
 
1. Gunnella F, Kunisch E, Maenz S, Bossert J, Jandt KD, Plöger F, Kinne RW. In vitro 
release of bioactive bone morphogenetic proteins (GDF5, BB-1, and BMP-2) from a PLGA 
fiber-reinforced, brushite-forming calcium phosphate cement (submitted to The Spine 
Journal 03-2018; under peer-review process). 
2. Bungartz M, Kunisch E, Horbert V, Xin L, Gunnella F, Mika J, Borowski J, Bischoff S, 
Schubert H, Sachse A, Illerhaus B, Günster J, Jandt KD, Kinne RW, Brinkmann O. First-
time systematic postoperative clinical assessment of a minimally invasive approach for 
lumbar ventrolateral vertebroplasty in the large animal model sheep. The Spine Journal 
2016;16(10):1263-1275. 
3. Gunnella F, Kunisch E, Bungartz M, Maenz S, Horbert V, Xin L, Mika J, Borowski J, 
Bischoff S, Schubert H, Hortschansky P, Sachse A, Illerhaus B, Günster J, Bossert J, Jandt 
KD, Plöger F, Kinne RW, Brinkmann O. Low-dose BMP-2 is sufficient to enhance the 
bone formation induced by an injectable, PLGA fiber-reinforced, brushite-forming cement 
in a sheep defect model of lumbar osteopenia. The Spine Journal 2017;17(11):1699-1711. 
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3. In vitro release of bioactive bone morphogenetic proteins (GDF5, BB-1, 
and BMP-2) from a PLGA fiber-reinforced, brushite-forming calcium 
phopshate cement  
 
Gunnella F, Kunisch E, Maenz S, Bossert J, Jandt KD, Plöger F, Kinne RW 
 
Submitted to The Spine Journal 
Ref.: Ms. No. SPINEE-D-18-00238 
 
 
Preface  
Particular properties of the CPC, such as biodegradability, fast setting ability and osteointegrative 
capacity, make them very attractive candidates as carriers for specific drug purposes. In the case of 
bone pathologies, proteins called BMPs, which are the most vital growth factors in bone formation 
and healing, can be incorporated in the CPC to further increase its osteoinductive capacity. This 
promising strategy leads to a sustained release and thus prolongs the half-life of growth factors. 
Several BMPs have been tested for their therapeutic efficacy in animal models of osteopenia. This 
has led to the approval of several clinical products containing rhBMP-2 or rhBMP-7 for either 
fracture treatment or spinal fusion in the 2000s, however with growing safety concerns. Recently, 
GDF-5 (also known as BMP-14) has shown positive effects in a sheep model of lumbar osteopenia 
by enhancing middle to long-term bone formation via changes in bone structure, formation, 
resorption, and compressive strength (Bungartz, Kunisch et al. 2017). A mutant GDF5 protein 
called BB-1, which carries two point mutations (methionine to valine at positions 453 and 456) in 
the BMPR-I binding site of GDF-5 and thus shows increased affinity to the BMPR-I (Kasten, 
Beyen et al. 2010), also significantly enhanced the bone formation induced by a PLGA-fiber 
reinforced CPC in sheep lumbar osteopenia for at least 3 months after a single therapeutic 
application (Gunnella, Kunisch et al. 2018). On the basis of the encouraging in vivo effects of 
GDF5, BB-1 and BMP-2, the present study aimed at analyzing the quantity and bioactivity of these 
BMPs released from a biodegradable, brushite-forming CPC in vitro. 
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4. First-time systematic postoperative clinical assessment of a minimally 
invasive approach for lumbar ventrolateral vertebroplasty in the large 
animal model sheep 
 
Bungartz M, Maenz S, Kunisch E, Horbert V, Xin L, Gunnella F, Mika J, Borowski J, 
Bischoff S, Schubert H, Sachse A, Illerhaus B, Günster J, Bossert J, Jandt KD, Kinne RW, 
Brinkmann O.  
 
The Spine Journal 2016;16(10):1263-1275. 
doi: 10.1016/j.spinee.2016.06.015. Epub 2016 Jun 23 
 
 
Preface  
As already discussed (Paragraph 1.5; pp. 23-24), large animal models are highly recommended for 
meaningful pre-clinical studies. In particular, in the case of experiments regarding the optimization 
of cement augmentation for vertebral body defects, the sheep spine may be a useful model due to 
its anatomic and biomechanical similarities with the human spine. To date, most of the studies in 
sheep were executed using “open surgery” and only a small number used minimally invasive 
techniques (Verron, Pissonnier et al. 2014). The aim of the study described in the current chapter 
was to develop a minimally invasive in vivo sheep model for lumbar ventrolateral vertebroplasty, 
including detailed analysis of intraoperative performance, trauma and functional impairment, 
reproducibility, resulting bone defects/cement filling, as well as defect healing and functional 
augmentation. 
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5. Low-dose BMP-2 is sufficient to enhance the bone formation induced 
by an injectable, PLGA fiber-reinforced, brushite-forming cement in a 
sheep defect model of lumbar osteopenia 
 
Gunnella F, Kunisch E, Bungartz M, Maenz S, Horbert V, Xin L, Mika J, Borowski J, 
Bischoff S, Schubert H, Hortschansky P, Sachse A, Illerhaus B, Günster J, Bossert J, Jandt 
KD, Plöger F, Kinne RW, Brinkmann O.  
 
The Spine Journal 2017;17(11):1699-1711. 
doi: 10.1016/j.spinee.2017.06.005. Epub 2017 Jun 12. 
 
 
Preface  
The minimally invasive vertebroplasty sheep model described in the previous chapter has proven 
suitable for future studies on the vertebral augmentation with resorbable and osteoconductive CPC. 
On the basis of the central role of BMP-2 in promoting bone repair, its extended clinical use, and 
the promising release data obtained in our previous study (Chapter 3; pp. 26-56), our minimally 
invasive lumbar osteopenia model was used to test an injectable, PLGA-fiber reinforced, brushite-
forming cement (CPC) containing the bone morphogenetic protein BMP-2.  
For the choice of the doses one important aspect was taken into consideration, i.e., the numerous 
serious adverse effects observed after the use of high doses between 1.95 and 40 mg of BMP-2 for 
spinal surgery, including back or leg pain, ectopic bone formation, wound complications, 
radiculitis, and retrograde ejaculation (Carragee, Hurwitz et al. 2011). For this reason, a fiber-
reinforced CPC was developed with considerably lower doses of BMP-2 (between 1 and 500 µg) 
and tested in our sheep model of ventrolateral vertebroplasty.  
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6. DISCUSSION  
The work described in the present thesis aimed at developing an injectable, poly (l-lactide-co-
glycolide) acid (PLGA)-fiber reinforced, brushite-forming cement (CPC) containing low-dose bone 
morphogenetic protein BMP-2, which can be used to replace the bioinert, non-resorbable, 
supraphysiologically stiff PMMA cements currently applied for the vertebroplasty/kyphoplasty of 
osteoporotic vertebral fractures. In order to confirm the novel PLGA-reinforced CPC as a suitable 
carrier for BMPs, the first study analyzed the quantity and bioactivity of BMPs released from CPC. 
Depending on the applied dosage and sample geometry, 25.7% of BMP-2 (within 14 days), 
between 10 and 34% of GDF5, and between 6 and 17% of BB-1 (within 30/31 days) were released 
in a bioactive configuration from the CPC, and this release was augmented by the presence of 
PLGA fibers, suggesting an active contribution of the bioactive BMPs to the healing of bone 
defects in vivo and validating the CPC as a long-lasting depot-system for a sustained release of the 
protein.                                                                                                                                                                                                                                                                                                                             
The development of new drugs or implant devices in the context of osteoporosis requires suitable 
animal models. The United States Food and Drug Administration (FDA) recommends that new 
therapeutic agents should undergo testing in the ovariectomized (OVX) rat and in a second, non-
rodent, large animal model with intracortical bone remodeling. Beside other animals, e.g. dogs, 
goats or primates, sheep have been most often used in previous orthopedic field of research, for 
their similarities to humans regarding bone structure, and anatomy of the thoracic and lumbar 
spine. For this reason, the second part of the study aimed at establishing a strictly minimally 
invasive large animal sheep model for lumbar ventrolateral vertebroplasty, which may represent an 
optimal basis for further studies with CPC. The new sheep model resulted in short operation times 
(28 ± 2 minutes; mean±standard error of the mean) and X-ray exposure (1.59 ± 0.12 minutes), very 
limited local trauma (score 0.00 ± 0.00 at 24 hours), short postoperative recovery (2.95 ± 0.29 
hours), and rapid decrease of the postoperative impairment score to 0 (3.28 ± 0.36 hours). In 
addition, the osteoconductivity of the CPC was demonstrated by osteodensitometry                   
(CPC > control), µCT (CPC > control and empty defect), histology/static histomorphometry     
(CPC > control and empty defect), fluorescence histomorphometry (CPC > control; all p < 0.05 for 
3 and 9 months), and compressive strength measurements (CPC numerically higher than control; 
102% for 3 months and 110% for 9 months). This sheep model was then used in a third study in 
which the bioresorbable, PLGA-fiber reinforced CPC was loaded with BMP-2, to further enhance 
and support the complete bone regeneration induced by CPC. Because of the numerous serious 
adverse effects which have been clinically reported using high doses between 1.95 and 40 mg of 
BMP-2 for spinal surgery, we aimed at considerably lower doses (1, 5, 100, 500 µg), demonstrating 
that a single local dose as low as ≤ 100 µg BMP-2 was sufficient to augment middle to long-term 
bone formation. In particular, compared to untouched controls (L1), CPC+fibers (L4) and/or 
CPC+fibers+BMP-2 (L5) significantly improved all parameters of bone formation, bone 
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resorption, and bone structure at 3 and 9 months. Compared to CPC without BMP-2, additional 
significant effects of BMP-2 were demonstrated for bone structure (bone volume/total volume, 
trabecular thickness, trabecular number) and formation (osteoid surface/bone surface and 
mineralizing surface/bone surface), as well as for the compressive strength. Several parameters still 
showed a significant effect of BMP-2 at the late time point 9 months, supporting the concept that a 
one-time therapeutic application is sufficient to induce middle to long-term effect. Such study also 
confirms, with the limitation of different load sharing forces in sheep and humans, the suitability of 
the present physiological and convenient osteopenia model for the analysis of vertebral 
augmentation with resorbable and osteoconductive CPC, as well as for dose-response studies with 
different molecules. The study was not designed as a safety study and was thus not suitable for a 
systematic assessment of the safety profile of the PLGA-fiber-reinforced, BMP-2-loaded CPC. 
However, within the limits of the study design, there were no signs of adverse effects previously 
reported after the clinical use of high-dose BMP-2 for spinal surgery and there were no signs of 
local inflammation, indicating that all the components of the new cement have no or negligible 
proinflammatory effects. The study also confirms that PLGA fibers at the present concentration 
have no negative effect on bone formation (Maenz, Brinkmann et al. 2017), but may rather enhance 
the osteoconductivity of the CPC. Furthermore, as previously published by our group, in vivo signs 
of systemic intravascular leakage after the injection of CPC were absent (Xin, Bungartz et al. 
2016). Interestingly, local intravascular leakage after in vivo application of CPC was only observed 
in a very limited percentage of vertebral bodies (approximately 10%) versus 53% in the case of 
high-viscosity PMMA cement (Kyphon, HV-R12, Medtronic Inc, Milan, Italy). The usage of CPC 
may thus reduce the risk of cement leakage in comparison with the commonly applied PMMA 
cement and may bear the potential to lower the frequency or severity of adverse effects.  
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7. CONCLUSION 
Our study demonstrated that the novel BMP-loaded CPC represents a suitable drug delivery system 
for the release of bioactive BMPs which can contribute to the healing of bone defects. Such effect 
was observed in vivo after minimally invasive injection of the BMP-2-loaded CPC. After 3 and 9 
months, the CPC  significantly enhanced the bone formation in sheep lumbar osteopenia, and may 
thus be a suitable candidate to replace the bioinert, non-resorbable, supraphysiologically stiff 
PMMA cements currently applied in the vertebroplasty/kyphoplasty of osteoporotic vertebral 
fractures. Also the two BMPs GDF5 and BB-1 have been tested in vivo by our group, and the 
results were comparable with the ones of BMP-2-loaded CPC (Bungartz, Kunisch et al. 2017, 
Gunnella, Kunisch et al. 2017). Future systematic safety studies will have to follow to validate the 
safety profile of low-dose BMP-2, and eventually, establish the use of BMP-loaded CPC for 
minimal surgery as well as for broader clinical applications.  
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A. APPENDIX 
 
   
 
Figure A.1: Morphology of the PLGA fibers. (a) Extruded PLGA ﬁber with smooth ﬁber 
morphology; (b) extruded PLGA ﬁber chopped in a cutting mill with 0.25 mm sieve insert; a pinch 
is visible (white arrow); (c) extruded PLGA ﬁber after cutting with scissors, damage of the ﬁber 
ending is detectable (black arrow); (d) cumulative ﬁber length distribution after cutting with the 3 
different approaches (*p ≤ 0.001 vs. 0.25 mm, #p ≤ 0.001 vs.1mm); (e) undulated fiber 
morphology after isopropanol treatment. [Maenz S et al. Enhanced mechanial properties of a novel, 
injectable, fiber-reinforced brushite cement. J Mech Behav Biomed Mater 2014 Nov; 39:328-38]   
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Figure A.2: Injectability and mechanical properties of ﬁber-reinforced CPCs with different ﬁber 
length and content. (a) Injectability (n=3); (b) diametral tensile strength (DTS) (n=10); (c) biaxial 
ﬂexural (n=10); (d) ﬂexural strength (n=10); (e) ﬂexural modulus (n=10); (f) work of fracture 
(WOF) (n=10). *p < 0.05 versus pure CPC; **p < 0.01 versus pure CPC; § p < 0.05 versus 
CPC+5% (w/w) 1 mm;  ++ p < 0.01 versus CPC+2.5% (w/w) 2 mm. [Maenz S et al. Enhanced 
mechanial properties of a novel, injectable, fiber-reinforced brushite cement. J Mech Behav 
Biomed Mater 2014 Nov; 39:328-38]   
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Determination of the histomorphometric parameters 
For the histological calculations, the following parameters were determined  in 20 fields of each 
individual vertebral body in the immediate vicinity of the injection channel using a Merz counting 
reticule (please refer to the Material and Methods section of Chapter 3; pag.): 
F = Number of measuring fields 
P = Number of hits (points) over mineralized bone and osteoid 
P0 = Number of hits over osteoid 
I = Total intersection number of the wave lines with the trabecular bone surface 
Io = Intersections of the wave lines with osteoid 
IH = Intersections of the wave lines with Howship`s lacunae containing osteoclasts  
k =  π × d / 4    [µm] (1)  
where d is the distance between 2 adjacent points in the counting net. 
 
The 7 parameters calculated below correspond to the recommendations of the International 
Committee of the American Society for Bone and Mineral Research (ASBMR):  
Bone volume/total volume (BV/TV): mineralized and non-mineralized fraction of the bone 
(includes the entire bone with cavities and appendix tissue) 
BV/TV = P × 100 / (F × 48) [%] (2) 
Trabecular thickness (Tb.Th): average absolute thickness of the trabeculae 
Tb.Th = P × k / I  [µm] (3) 
Trabecular number (Tb.N): number of trabeculae per mm (derived from bone volume/total volume 
and trabecular thickness) 
Tb.N = BV/TV / Tb.Th  [1/mm] (4) 
Osteoid volume (OV/BV): non-mineralized fraction of the bone  
Figure A.3: Schematic representation of the Merz grid. [Merz WA. Die Streckenmessung an  
gerichteten Strukturen im Mikroskop und ihre Anwendung zur Bestimmung von Oberflächen-
Volumen-Relationen im Knochengewebe. Mikroskopie, 22:132–142, 1967] 
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OV/BV = P0 × 100 / P  [%] (5) 
Osteoid surface (OS/BS): non-mineralized surface fraction related to the total bone surface 
independent of the osteoblast coverage 
OS/BS =  IO × 100 / I   [%] (6) 
Osteoid thickness (O.Th): average absolute thickness of non-mineralized bone tissue 
O.Th = P0 × k × 100 / IO [µm] (7) 
Eroded Surface (ES/BS): surface proportion of resorption lacunae related to the total trabecular 
bone surface independent of the osteoclast coverage 
ES/BS = IH × 100 / I   [%] (8) 
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